Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

Paolo A. Ascierto; Kim Margolin

doi:10.1002/cncr.28622

Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

Istituto Nazionale Tumori Fondazione G. Pascale

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1617-1619
Number of pages	3
Journal	Cancer
Volume	120
Issue number	11
DOIs	https://doi.org/10.1002/cncr.28622
Publication status	Published - Jun 1 2014

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1002/cncr.28622

Cite this

@article{63ed54152c85405b807b83b2d036aee8,

title = "Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma",

author = "Ascierto, {Paolo A.} and Kim Margolin",

year = "2014",

month = jun,

day = "1",

doi = "10.1002/cncr.28622",

language = "English",

volume = "120",

pages = "1617--1619",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "11",

}

TY - JOUR

T1 - Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

AU - Ascierto, Paolo A.

AU - Margolin, Kim

PY - 2014/6/1

Y1 - 2014/6/1

UR - http://www.scopus.com/inward/record.url?scp=84901358299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901358299&partnerID=8YFLogxK

U2 - 10.1002/cncr.28622

DO - 10.1002/cncr.28622

M3 - Article

C2 - 24577788

AN - SCOPUS:84901358299

SN - 0008-543X

VL - 120

SP - 1617

EP - 1619

JO - Cancer

JF - Cancer

IS - 11

ER -

Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this